The FDA has lifted Risk Evaluation and Mitigation Strategies (REMS) restrictions on six approved CAR T cell therapies targeting BCMA and CD19, citing established management protocols and extensive clinical experience. This regulatory shift is intended to ease administrative burdens and facilitate broader use of these potentially curative therapies in community settings. Industry analysts and cell therapy advocates welcome the move as a step toward faster patient access and reduced treatment delays.